Overview
Rubraca is approved by the U.S. Food and Drug Administration (FDA) for the treatment of metastatic castration-resistant prostate cancer (mCRPC) in adults who have a BRCA gene mutation (change) and who have already been treated with androgen receptor-directed therapy. People must be selected for this treatment using an FDA-approved companion diagnostic test. Rubraca is also known by its drug name, rucaparib.

Rubraca is a type of drug known as a poly (ADP-ribose) polymerase (PARP) inhibitor. It works by blocking an enzyme involved in repairing damaged DNA. In cancer cells with BRCA mutations, this leads to more DNA damage and can cause the cancer cells to die.

How do I take it?
Prescribing information states that Zoladex is typically administered as a subcutaneous (under the skin) implant every 12 weeks. The implant is placed into the anterior abdominal wall (lower belly area), just below the navel. The drug should be given exactly as prescribed by a healthcare provider.

Side effects
Common side effects of Rubraca in people with BRCA-mutated prostate cancer include fatigue or weakness, muscle and bone pain, nausea, anemia (low red blood cell count), decreased appetite, increased liver enzymes, constipation, diarrhea, vomiting, low platelet count, shortness of breath, increased blood creatinine (a sign of kidney function), swelling, dizziness, weight loss, abdominal pain, altered taste, rash, peripheral neuropathy (nerve damage), urinary tract infection, cough, headache, bleeding, low white blood cell count, and sensitivity to sunlight.

Rare but serious side effects may include myelodysplastic syndrome or acute myeloid leukemia (types of blood cancers), which can be fatal. These risks require regular blood monitoring. Rubraca can also harm an unborn baby, so effective contraception is advised during treatment.

For more information about this treatment, visit:
Label: Rubraca — Rucaparib Tablet, Film Coated — DailyMed